LONG-TERM EFFECTS OF A CONVERTING-ENZYME-INHIBITOR AND A CALCIUM-CHANNEL BLOCKER ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL-HYPERTENSION

被引：40

作者：

BIGAZZI, R

BIANCHI, S

BALDARI, D

SGHERRI, G

BALDARI, G

CAMPESE, VM

机构：

[1] UO di Nefrologia e Dialisi, Spedali Riuniti, Livorno

[2] Division of Nephrology, University of Southern California, Los Angeles, CA

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 02期

关键词：

ESSENTIAL HYPERTENSION; MICROALBUMINURIA; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; ENALAPRIL; NICARDIPINE;

D O I：

10.1093/ajh/6.2.108

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Microalbuminuria in patients with essential hypertension is associated with increased incidence of cardiovascular morbidity and mortality. Reduction of urinary albumin excretion (UAE) with therapy could reduce cardiovascular events. The long-term effect of commonly used antihypertensive agents on UAE has not been properly investigated. In the present study, we have prospectively studied the effects of therapy for 24 months with a converting enzyme inhibitor, enalapril, or a calcium channel blocker, nicardipine, on UAE in 40 patients with essential hypertension and microalbuminuria. Enalapril and nicardipine were equally effective in reducing arterial pressure. However, enalapril decreased UAE from 77.1 +/- 10.4 to 30.4 +/- 7.9 mg/24 h after 1 year, and to 24.7 +/- 4.8 (P < .01) after 2 years of therapy. UAE however, did not change in patients treated with nicardipine (from 65.2 +/- 12 to 73 +/- 14 after 1 year, and to 52.7 +/- 21 mg/24 h after 2 years of therapy). The impact of reducing UAE on overall cardiovascular morbidity and mortality and on future progression of renal failure in patients with essential hypertension remains to be established.

引用

页码：108 / 113

页数：6

共 45 条

[31] Insua A., Ribstein J., Mimean A., Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy, Postgrad Med J, 64, pp. 59-62, (1988)
[32] Ritz E., Fliser D., Keller H., Reisch C., Are newer antihypertensive agents really more effective than traditional drugs in progressive renal disease?, Am J Kidney Dis, 17, pp. 76-80, (1991)
[33] Baba T., Murabayashi S., Takebe K., Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (Noninsulin-dependent) diabetic patients with microalbuminuria: A randomized controlled trial, Diabetologia, 32, pp. 40-44, (1989)
[34] Bakris G.L., Effects of diltiazem or lisinopril on massive proteinuria associated with diabetic nephropathy, Ann Int Med, 112, pp. 707-708, (1990)
[35] Bakris G.L., Barnhill B.W., Sadler R., Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection, Kidney Int, 41, pp. 912-919, (1992)
[36] Comparison between perindopril and nifedipine in hyperten sive and normotensive diabetic patients with microalbuminuria, Br Med J, 302, pp. 210-216, (1991)
[37] Apperloo A.J., De Zeeuw D., Sluiter H.E., De Jong P.E., Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease, Br Med J, 303, pp. 821-824, (1991)
[38] Rosenberg M.E., Hostetter T.H., Comparative effects of antihypertensives on proteinuria: Angiotensin-converting enzyme inhibitor versus alpha 1-antagonist, Am J Kidney Dis, 18, pp. 472-482, (1991)
[39] Bjorck S., Mulec H., Johnsen S.A., Et al., Renal protective effect of enalapril in diabetic nephropathy, Br Med J, 304, pp. 339-343, (1992)
[40] Rudberg S., Aperia A., Freyschuss U., Persson B., Enalapril reduces microalbuminuria in young normotensive type 1 (Insulin-dependent) diabetic patients irrespective of its hypotensive effect, Diabetologica, 33, pp. 470-476, (1990)

← 1 2 3 4 5 →